Navigation Links
WuXi PharmaTech Announces Second-Quarter 2009 Results
Date:8/11/2009

865 14,279 Deferred revenue 3,837 3,373 Advanced subsidies 3,047 3,080 Other taxes payable 3,320 5,742 Other current liabilities 5,319 3,448 Liabilities of discontinued operations (Note 1) 83 1,495 Total current liabilities 97,945 58,804 Non-current liabilities: Long-term debt, excluding current portion 2,242 2,305 Advanced subsidies 1,706 1,819 Convertible notes 35,864 35,864 Other non-current liabilities 7,389 6,731 Total non-current liabilities 47,201 46,719 Total liabilities 145,146 105,523 Shareholders' equity: Ordinary shares ($0.02 par value, 5,002,500,000 authorized as of June 30, 2009 and December 31, 2008, respectively; 544,157,080 and 529,385,590 issued and outstanding as of June 30, 2009, and December 31, 2008, respectively) 10,883 10,588 Additional paid-in capital 314,329 324,629 Accumulated deficit (95,084) (121,505) Accumulated other comprehensive income 16,957 17,164 Total shareholders' equity 247,085 230,876 Total liabilities and shareholders' equity 392,231 336,399 Note 1: The biologics manufacturing operations in Philadelphia, which management decided to close in December 2008, were classified as discontinued operations. Note 2: Assets of discontinued operations included assets h
'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2009 Annual General Meeting
2. WuXi PharmaTech Schedules Second-Quarter 2009 Earnings Release
3. WuXi PharmaTech Receives Award from BASF
4. WuXi PharmaTech Named a Top Ten Chinese Outsourcing Enterprise
5. WuXi PharmaTech Appoints Felix Hsu as Senior Vice President of U.S. Operations
6. WuXi PharmaTech Appoints Wei-Min Chang as Vice President of Operations and General Manager of SynTheAll Manufacturing Facility, Eric Gu as Vice President of Business Development for Manufacturing Services
7. WuXi PharmaTech to Present at Third Annual Jefferies Healthcare Conference
8. WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release
9. Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA
10. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
11. The Fitzsimons Redevelopment Authority Selects Pharmatech Oncology as Preferred Vendor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 2014 WriteResult, LLC – a premier ... again shown superiority when it comes to meeting the ... ePRO portion of their most recent study closeout on-time ... chose WriteResult’s digital writing platform to collect Patient Reported ... to complete drew data from a number of assessments ...
(Date:8/26/2014)... An analysis by Replikins, Ltd. of Pubmed ... CoV virus strains has revealed extensive conservation and ... conservation and sharing of specific Replikin gene structures has ... as it did for the H5N1 influenza vaccine and ... been found to be effective (1,2). ...
(Date:8/26/2014)... 2014 An analysis by Replikins, Ltd. of ... virus strains in Pubmed, has revealed extensive conservation and ... conservation and sharing of specific Replikin gene structures has ... as it did for the H5N1 influenza vaccine and ... been found to be effective (1,2). ...
(Date:8/26/2014)... Vycom announced today that Modutek Corporation ... equipment, has selected its Flametec materials for a ... Beams (FRIB). This involved the creation of a ... Flametec PVC-C and Kytec PVDF material to clean superconducting ... linear accelerator (known as LINAC). , ...
Breaking Biology Technology:A Perfect Record: WriteResult Maintains a 100% On-Time ePRO Record with Latest Irritable Bowel (IBS) Study Data Lock 2Modutek Selects Vycom’s Flametec Materials for Michigan State University’s Superconductor Equipment 2Modutek Selects Vycom’s Flametec Materials for Michigan State University’s Superconductor Equipment 3
... , , NEW YORK, Aug. 13 ... the second quarter ended June 30, 2009. , , Revenues ... in 2008. Net loss for the second quarter of 2009 was $103,330, ... Basic net loss per share for the second quarter of 2009 was $0.01, ...
... , , MANHATTAN, ... around the world hundreds of millions of dollars each year. , ... Hesse and Bob Rowland have been working to create new vaccines ... and its associated diseases continue to emerge around the world," Hesse ...
... FORT LAUDERDALE, Fla., Aug. 13 OmniComm Systems, Inc. ... capture (EDC) solutions for clinical trials, today announced that it ... Organization (CRO) to provide eClinical solutions for a pivotal Phase ... serve to establish the safety and efficacy of investigational new ...
Cached Biology Technology:Cadus Reports Second Quarter 2009 Results 2Cadus Reports Second Quarter 2009 Results 3Cadus Reports Second Quarter 2009 Results 4Cadus Reports Second Quarter 2009 Results 5K-State's Biosecurity Research Institute Gives Researchers the Tools Needed to Study Diseases That Cost Pig Producers Hundreds of Millions of Dollars Each Year 2K-State's Biosecurity Research Institute Gives Researchers the Tools Needed to Study Diseases That Cost Pig Producers Hundreds of Millions of Dollars Each Year 3Leading European Contract Research Organization Selects OmniComm to Provide eClinical Solutions for Important Phase III Study 2
(Date:8/27/2014)... that a deficiency in serotonin a chemical messenger ... depression. In the journal ACS Chemical Neuroscience , ... serotonin in their brains (and thus should have been ... , Donald Kuhn and colleagues at the John ... School of Medicine note that depression poses a major ...
(Date:8/27/2014)... have largely succeeded in sidelining the use of ... its potential contributions to Americans, health conditions. But ... best way to assuage the nation,s insatiable sweet ... & Engineering News (C&EN), the weekly news ... the article, Stephen Ritter, a senior correspondent at ...
(Date:8/27/2014)... can be weaned later with no negative effects on ... at the University,s Roseworthy campus, published in the journal ... for pig producers. It allows improvements in piglet health ... usually start their oestrous cycles again during lactation, only ... says Ms Alice Weaver, PhD candidate with the School ...
Breaking Biology News(10 mins):New study throws into question long-held belief about depression 2Piglet weaning age no bar to litter frequency 2
... identify new anti-cancer, anti-infection response control mechanism , ... de recherches cliniques de Montréal (IRCM), and his ... the prestigious journal Nature Immunology of Nature Publishing ... treatment of cancers and infectious diseases. Current treatments ...
... to clone human embryos from eggs that have been ... easier for scientists to create embryonic stem cell lines ... and sperm for infertile couples, the 21st annual conference ... heard today (Monday 20 June). , Until now, scientists ...
... the structure of a crucial human immune system molecule ... an upcoming issue of the journal Science, the protein ... 23 leucine-rich repeats (LRRs). , The structure reveals details ... essential step toward fully understanding the critical role this ...
Cached Biology News:Major breakthrough in the treatment of cancers and infectious diseases 2Scientists succeed in cloning human embryos from eggs matured in the lab 2Scientists succeed in cloning human embryos from eggs matured in the lab 3Scripps research scientists solve structure of a critical innate immune system protein 2Scripps research scientists solve structure of a critical innate immune system protein 3Scripps research scientists solve structure of a critical innate immune system protein 4